Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 4/20 | 0.74 |
| ▸ | TMIGD3 | P0DMS9 | 3/20 | 0.74 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.74 |
| ▸ | HTT | P42858 | 1/20 | 0.74 |
| ▸ | RAB9A | P51151 | 2/20 | 0.73 |
| ▸ | NPC1 | O15118 | 1/20 | 0.73 |
| ▸ | HPGD | P15428 | 1/20 | 0.73 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.73 |
| ▸ | CDK1 | P06493 | 3/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.70 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.64 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.64 |
| ▸ | CDK2 | P24941 | 1/20 | 0.64 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.64 |
| ▸ | PDE4A | P27815 | 1/20 | 0.64 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.64 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.64 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.64 |
| ▸ | CTSL | P07711 | 1/20 | 0.62 |
| ▸ | PI4KA | P42356 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22571186 | 0.88 | TMIGD3 (0.81) | ADORA2ATMIGD3ADORA1HTTRAB9A | |
| SCHEMBL5125772 | 0.88 | HTT (0.73) | ADORA2ATMIGD3ADORA1HTTRAB9A | |
| SCHEMBL31711721 | 0.85 | HTT (0.75) | ADORA2ATMIGD3ADORA1HTTRAB9A | |
| SCHEMBL458946 | 0.85 | TMIGD3 (0.77) | ADORA2ATMIGD3ADORA1HTTRAB9A | |
| SCHEMBL5122955 | 0.84 | PDE4A (0.85) | ADORA2ATMIGD3ADORA1HTTPDE4A | |
| SCHEMBL31088348 | 0.84 | HTT (0.68) | ADORA2ATMIGD3ADORA1HTTRAB9A | |
| SCHEMBL2049171 | 0.84 | RAB9A (1.00) | ADORA2ATMIGD3ADORA1HTTRAB9A | |
| SCHEMBL7644240 | 0.84 | HTT (0.68) | ADORA2ATMIGD3ADORA1HTTRAB9A | |
| SCHEMBL28740202 | 0.84 | RAB9A (0.78) | ADORA2ATMIGD3ADORA1HTTRAB9A | |
| SCHEMBL4382069 | 0.82 | CDK1 (1.00) | ADORA2ATMIGD3ADORA1HTTRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230279007-A1 | Compounds for Improving mRNA Splicing | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2023-09-07 | — | — | US | disclosed |
| US-11702417-B2 | Compounds for improving mRNA splicing | THE GENERAL HOSPITAL CORPORATION (US) | 2023-07-18 | — | — | US | disclosed |
| US-20200283441-A1 | Compounds for Improving mRNA Splicing | THE GENERAL HOSPITAL CORPORATION | 2020-09-10 | — | — | US | disclosed |
| US-10676475-B2 | Compounds for improving mRNA splicing | THE GENERAL HOSPITAL CORPORATION (US) | 2020-06-09 | — | — | US | disclosed |
| US-20180118748-A1 | Compounds for Improving mRNA Splicing | THE GENERAL HOSPITAL CORPORATION | 2018-05-03 | — | — | US | disclosed |
| WO-2016115434-A1 | COMPOUNDS FOR IMPROVING MRNA SPLICING | THE GENERAL HOSPITAL CORPORATION (US) | 2016-07-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230279007-A1 | Compounds for Improving mRNA Splicing | RTCB, RBM17, HNRNPA2B1 | ADORA2A 1652/4885TMIGD3 3572/4885ADORA1 2593/4885 |
| US-10676475-B2 | Compounds for improving mRNA splicing | RTCB, RBM17, HNRNPA2B1 | ADORA2A 1652/4885TMIGD3 3572/4885ADORA1 2593/4885 |
| US-20180118748-A1 | Compounds for Improving mRNA Splicing | RTCB, RBM17, HNRNPA2B1 | ADORA2A 1652/4885TMIGD3 3572/4885ADORA1 2593/4885 |
| US-11702417-B2 | Compounds for improving mRNA splicing | RTCB, RBM17, HNRNPA2B1 | ADORA2A 1652/4885TMIGD3 3572/4885ADORA1 2593/4885 |
| US-20200283441-A1 | Compounds for Improving mRNA Splicing | RTCB, RBM17, HNRNPA2B1 | ADORA2A 1652/4885TMIGD3 3572/4885ADORA1 2593/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.